Bristol Myers Squibb partners with Anthropic to deploy Claude AI across research, development, manufacturing, and medical affairs enterprise‑wide.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Bristol Myers Squibb has deepened its commitment to artificial intelligence with a new collaboration with Anthropic, deploying Claude across core scientific, operational, and corporate functions. The rollout will provide more than 30,000 employees with access to agentic AI integrated into the company’s internal systems and workflows.
The partnership reflects a broader industry transition beyond standalone chatbot tools toward AI systems capable of executing complex tasks across fragmented enterprise environments. Bristol Myers Squibb plans to embed Claude into research, clinical development, manufacturing, medical affairs, and software engineering operations.
In research, Claude will analyze decades of proprietary molecular, scientific, and clinical datasets to support target identification and optimization across oncology, hematology, neuroscience, and immunology programs. Within drug development, the company will apply AI‑assisted automation to clinical study reports, patient safety narratives, and regulatory documentation, subject to applicable regulatory guidance on AI use in submissions. The approach is intended to shorten timelines between trial completion and regulatory filing.
Manufacturing and quality operations represent another major focus area. Claude will support root‑cause investigations, Corrective and Preventive Action documentation, and AI‑supported batch release decisions designed to accelerate product delivery while maintaining compliance standards. Commercial and medical affairs teams will also use the platform to convert field insights into structured intelligence for more personalized engagement with healthcare professionals.
The deployment builds on more than three years of internal AI infrastructure investment. Bristol Myers Squibb previously established a proprietary enterprise platform that provides employees with access to multiple frontier AI models under a broader multi‑vendor strategy spanning several leading providers.
Greg Meyers, Executive Vice President and Chief Digital & Technology Officer at Bristol Myers Squibb, said the collaboration focuses on unlocking institutional knowledge fragmented across disconnected enterprise systems. He added that future biopharma leadership will depend on how effectively companies operationalize AI across scientific and operational functions.
Anthropic’s Head of Life Sciences, Eric Kauderer‑Abrams, noted that Claude’s agentic AI capabilities could support tasks ranging from generating clinical study reports directly from trial datasets to tracing manufacturing deviations in real time within regulated environments.
The collaboration positions Bristol Myers Squibb among a growing cohort of large pharmaceutical companies operationalizing generative and agentic AI across discovery, development, manufacturing, and commercialization to accelerate timelines and improve efficiency.
By embedding Claude into enterprise workflows, the company aims to unlock institutional knowledge and streamline processes across the drug lifecycle, reinforcing its position at the forefront of AI‑enabled biopharma innovation.
Reference
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.